NeuroSigma, Inc. is a Los Angeles-based bioelectronics company commercializing external trigeminal nerve stimulation (eTNS) technology. NeuroSigma's Monarch eTNS® System is a bioelectronic medical device that uses external trigeminal nerve stimulation to treat neurological and neuropsychiatric disorders. In 2019, the Monarch eTNS System became the first-ever medical device cleared by FDA for treating pediatric ADHD. The new Monarch Pediatric Care Co-Pay Program is making eTNS therapy available to a substantially greater number of children diagnosed with ADHD.
NeuroSigma Address
10960 Wilshire Boulevard Los Angeles, CA United States